PKU HealthCare Corp.,Ltd. engages in the research, development, production, and sale of chemical pharmaceutical preparations, pharmaceutical distribution, and medical services in China. The company offers anti-infectives, analgesics, psychotropic drugs, digestive system drugs, and cardiovascular drugs; procurement and pharmacy outsourcing; and cancer screening, health management, and treatment services related to healthcare management and care delivery, as well as involved in distribution, retail, and hospital sales of pharmaceuticals, medical devices, and consumables. It also provides ceftriaxone sodium, meropenem, and cefminox sodium for injection; moxifloxacin hydrochloride injection; clindamycin palmitate hydrochloride granules; naphazoline capsules; celecoxib capsules; dextroketoneprofen tablets and capsules; buspirone hydrochloride tablets; and olanzapine tablets. The company was formerly known as PUK International Hospital Group Southwest Synthetic Pharmaceutical Corp., Ltd. and changed its name to PKU HealthCare Corp., Ltd. in November 2013. PKU HealthCare Corp.,Ltd. was founded in 1993 and is headquartered in Chongqing, China.
Research context
PKU HealthCare Corp.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
PKU HealthCare Corp.,Ltd is currently in a long term uptrend where the price is trading 6.6% above its 200 day moving average.
From a valuation standpoint, the stock is 80.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
PKU HealthCare Corp.,Ltd's total revenue sank by 9.5% to $565M since the same quarter in the previous year.
Its net income has increased by 8.2% to $16M since the same quarter in the previous year.
Finally, its free cash flow grew by 65.1% to $-14M since the same quarter in the previous year.
Based on the above factors, PKU HealthCare Corp.,Ltd gets an overall score of 4/5.